TRBV29-1: A Non-Coding RNA Molecule as A Cancer Drug Target (G28558)

Target Name: TRBV29-1

NCBI ID: G28558

TRBV29-1

Other Name(s): TCRBV29S1 | TRBV291 | TCRBV4S1A1T | T cell receptor beta variable 29-1

TRBV29-1: A Non-Coding RNA Molecule as A Cancer Drug Target

TRBV29-1 (TcRBV29S1) is a non-coding RNA molecule that has been identified as a potential drug target (also known as a biomarker) in the field of cancer. It is a key regulator of the T cell receptor (TCR) complex, which is responsible for cell signaling and immune response.

The TRBV29-1 gene was first identified in the genomic sequence data by using bioinformatic tools to search for RNA molecules that interacted with the TCR灏? subunit. The TRBV29-1 RNA was found to interact with the TCR灏? subunit with high affinity, and the interaction was suggested to be conserved across different species.

The TRBV29-1 RNA is composed of 194 amino acid residues and has a calculated molecular weight of 20.8 kDa. It is predominantly expressed in human tissues, including lung, breast, and colon.

In cancer, the TCR system is often disrupted, leading to an imbalance in T cell activity that contributes to the development and progression of cancer. The TRBV29-1 RNA has been shown to play a role in regulating the TCR system in cancer cells by regulating the expression of genes involved in cell signaling and immune response.

One of the key functions of the TRBV29-1 RNA is its ability to regulate the expression of genes involved in the TCR signaling pathway. This is accomplished through the use of a variety of mechanisms, including the binding of TRBV29-1 RNA to specific DNA sequences in the TCR gene locus, the regulation of gene expression by the TRBV29-1 RNA itself, and the regulation of gene expression by other molecules, such as RNA-binding protein (RBP).

The TRBV29-1 RNA has been shown to play a role in regulating the expression of genes involved in cell signaling and immune response, including the TCR signaling pathway. For example, studies have shown that the TRBV29-1 RNA can suppress the expression of genes involved in the TCR signaling pathway, such as the tyrosine kinase receptor (TKR) gene, which is involved in cell signaling.

In addition to its role in regulating gene expression, the TRBV29-1 RNA has also been shown to play a role in regulating the structure and function of the TCR灏? subunit. This is accomplished through the use of a variety of mechanisms, including the regulation of protein stability and the ability to interact with specific DNA sequences in the TCR gene locus.

The TRBV29-1 RNA has been shown to play a role in regulating the structure and function of the TCR灏? subunit by the regulation of protein stability. This is accomplished through the use of a variety of mechanisms, including the regulation of the stability of the TCR灏? subunit through the use of a variety of post-translational modifications, such as phosphorylation and ubiquitination.

In conclusion, TRBV29-1 (TcRBV29S1) is a non-coding RNA molecule that has been identified as a potential drug target (also known as a biomarker) in the field of cancer. It is a key regulator of the T cell receptor (TCR ) complex and has been shown to play a role in regulating gene expression and the structure and function of the TCR灏? subunit. Further research is needed to fully understand the role of the TRBV29-1 RNA in cancer development and progression.

Protein Name: T Cell Receptor Beta Variable 29-1

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV29-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV29-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets